Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rocket Pharmaceuticals, Inc. filings document regulatory, financial, governance, and capital-structure disclosures for a biotechnology company developing and commercializing genetic therapies for rare disorders. Recent 8-K reports cover quarterly and annual operating results, FDA-related events for KRESLADI, Priority Review Voucher monetization, and clinical-program updates for cardiovascular gene therapy candidates.
The filing record also includes definitive proxy materials for annual-meeting governance matters and material-agreement disclosures related to an at-the-market common stock offering program under a shelf registration statement. These documents describe board and shareholder-vote matters, equity financing mechanics, common stock structure, business risks, and formal disclosure controls around product approvals and development programs.
Rocket Pharmaceuticals, Inc. executive Joseph Manhede, the Principal Accounting Officer, filed an initial ownership report showing his equity position in the company. The filing reflects 52,576 shares of Common Stock held directly, represented by restricted stock units that convert to common shares on a one-for-one basis.
These RSUs were granted on May 4, 2026. One-third of the units will vest on May 4, 2027, with the remaining units vesting in equal quarterly installments over the following two years. The filing does not report any open-market purchases or sales, only the existing equity award and its vesting schedule.
ROCKET PHARMACEUTICALS, INC. director and 10% owner Roderick Wong received new equity awards in the form of common stock and options. He was granted 27,832 restricted stock units that convert into common shares on a one-for-one basis and vest in full on June 18, 2027. He also received a stock option for 78,960 shares of common stock at an exercise price of $3.35 per share, which becomes fully vested and exercisable on June 18, 2027 and expires on June 18, 2036. Following these awards, he holds 75,499 common shares directly and 18,188,457 shares indirectly through investment funds managed by RTW Investments, LP.
Rocket Pharmaceuticals director Peter Fong received equity awards as part of his compensation. He was granted 22,862 restricted stock units that convert into common stock on a one-for-one basis and will vest in full on June 18, 2027. He also received a stock option to purchase 64,860 shares of common stock at an exercise price of $3.35 per share, which will become fully vested and exercisable on June 18, 2027 and will expire on June 18, 2036. Following the restricted stock unit grant, his direct common stock holdings reported in this filing total 76,195 shares.
ROCKET PHARMACEUTICALS, INC. director Mikael Dolsten reported routine equity compensation awards rather than open-market trades. He received 22,862 restricted stock units that convert into common stock on a one-for-one basis and 64,860 stock options with an exercise price of $3.35 per share.
The RSUs and options both vest in full on June 18, 2027, with the options expiring on June 18, 2036. After the RSU grant, Dolsten directly holds 67,082 shares of common stock. The filing reflects compensation-related acquisitions, not purchases or sales in the market.
ROCKET PHARMACEUTICALS, INC. director Fady Ibraham Malik reported receiving equity awards tied to the company’s common stock. He was granted 22,862 restricted stock units that convert into common shares on a one-for-one basis and will vest in full on June 18, 2027.
He also received a stock option covering 64,860 shares of common stock at an exercise price of $3.35 per share, which will become fully vested and exercisable on June 18, 2027 and expires on June 18, 2036. Following the RSU grant, he directly holds 52,862 common shares.
ROCKET PHARMACEUTALS, INC. director David P. Southwell reported equity awards, not open-market trades. He received 22,862 restricted stock units (RSUs) that convert one-for-one into common stock and will vest in full on June 18, 2027. He was also granted a stock option for 64,860 shares of common stock at an exercise price of $3.35 per share, which becomes fully vested and exercisable on June 18, 2027 and expires on June 18, 2036. Following these awards, he directly owns 54,522 shares of common stock and indirectly holds 113,124 shares through The David P. Southwell Irrevocable Trust dated April 14, 2024.
Rocket Pharmaceuticals director Carsten Boess reported stock-based awards that increase his equity stake in the company. He received 22,862 restricted stock units that convert into common stock on a one-for-one basis and will vest in full on June 18, 2027. He also received options covering 64,860 shares of common stock at an exercise price of $3.35 per share, which will become fully vested and exercisable on June 18, 2027. Following the grant, his direct holdings of common stock total 52,862 shares, with the new option award providing additional potential future ownership.
Rocket Pharmaceuticals, Inc. announced leadership changes in its finance organization. John Militello, VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, has resigned effective July 7, 2026 to pursue other opportunities. Joseph Manhede, currently Associate Vice President, Corporate Controller, will become Principal Accounting Officer effective July 8, 2026.
Manhede, age 48, joined Rocket in April 2026 and previously held senior finance roles at Outlook Therapeutics, Amneal Pharmaceuticals, Unilife Corporation and Celator Pharmaceuticals after starting his career at Deloitte. He is a CPA with an MBA from Holy Family University. The company states there are no new compensatory arrangements or related-party transactions tied to his designation.
Rocket Pharmaceuticals has completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company for $180 million in gross, non-dilutive proceeds. The voucher was granted following FDA approval of KRESLADI, Rocket’s gene therapy for severe leukocyte adhesion deficiency-I.
Rocket previously reported cash, cash equivalents and investments of $144.4 million as of March 31, 2026. Pro forma for the voucher sale, this increases to about $322.6 million, which the company expects will fund operations into the second quarter of 2028.